MedTrace Logo

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

NCT01601119 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 545

Last updated 2015-05-29

No results posted yet for this study

Summary

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

Conditions

Interventions

DRUG

Rebif

The subjects will receive Rebif as per the current practices or as directed by the physician.

OTHER

Other: Disease modifying therapies (DMT)

The subjects will receive other DMTs as per the current practices or as directed by the physician.

Sponsors & Collaborators

  • Merck Serono Limited, UK

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Serono Limited, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United Kingdom

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601119 on ClinicalTrials.gov